These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 16421458

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Incidence of Neutropenia With Valproate and Quetiapine Combination Treatment in Subjects With Acquired Brain Injuries.
    Park HJ, Kim JY.
    Arch Phys Med Rehabil; 2016 Feb; 97(2):183-8. PubMed ID: 26427579
    [Abstract] [Full Text] [Related]

  • 23. Efficacy of quetiapine monotherapy in rapid-cycling bipolar disorder in comparison with sodium valproate.
    Langosch JM, Drieling T, Biedermann NC, Born C, Sasse J, Bauer H, Walden J, Bauer M, Grunze H.
    J Clin Psychopharmacol; 2008 Oct; 28(5):555-60. PubMed ID: 18794653
    [Abstract] [Full Text] [Related]

  • 24. Hippocampal 1H MRS in patients with bipolar disorder taking valproate versus valproate plus quetiapine.
    Atmaca M, Yildirim H, Ozdemir H, Ogur E, Tezcan E.
    Psychol Med; 2007 Jan; 37(1):121-9. PubMed ID: 17094813
    [Abstract] [Full Text] [Related]

  • 25. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy.
    Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P.
    Arch Gen Psychiatry; 2000 Jun; 57(6):553-9. PubMed ID: 10839333
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder.
    Spina E, D'Arrigo C, Santoro V, Muscatello MR, Pandolfo G, Zoccali R, Diaz FJ, de Leon J.
    Ther Drug Monit; 2009 Dec; 31(6):758-63. PubMed ID: 19865002
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade.
    Tauscher-Wisniewski S, Kapur S, Tauscher J, Jones C, Daskalakis ZJ, Papatheodorou G, Epstein I, Christensen BK, Zipursky RB.
    J Clin Psychiatry; 2002 Nov; 63(11):992-7. PubMed ID: 12444812
    [Abstract] [Full Text] [Related]

  • 30. Pharmacokinetics of quetiapine in elderly patients with selected psychotic disorders.
    Jaskiw GE, Thyrum PT, Fuller MA, Arvanitis LA, Yeh C.
    Clin Pharmacokinet; 2004 Nov; 43(14):1025-35. PubMed ID: 15530131
    [Abstract] [Full Text] [Related]

  • 31. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
    Tauscher J, Hussain T, Agid O, Verhoeff NP, Wilson AA, Houle S, Remington G, Zipursky RB, Kapur S.
    Am J Psychiatry; 2004 Sep; 161(9):1620-5. PubMed ID: 15337652
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Individual clearance and therapeutic drug monitoring of quetiapine in clinical practice.
    Wittmann M, Hausner H, Köstlbacher A, Hajak G, Haen E.
    Neuro Endocrinol Lett; 2010 Sep; 31(2):203-7. PubMed ID: 20424588
    [Abstract] [Full Text] [Related]

  • 34. A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone.
    Lee SY, Park MH, Patkar AA, Pae CU.
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar 30; 35(2):490-6. PubMed ID: 21146575
    [Abstract] [Full Text] [Related]

  • 35. Review of quetiapine and its clinical applications in schizophrenia.
    Kasper S, Müller-Spahn F.
    Expert Opin Pharmacother; 2000 May 30; 1(4):783-801. PubMed ID: 11249516
    [Abstract] [Full Text] [Related]

  • 36. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release.
    Figueroa C, Brecher M, Hamer-Maansson JE, Winter H.
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar 17; 33(2):199-204. PubMed ID: 18948162
    [Abstract] [Full Text] [Related]

  • 37. Quetiapine in hospitalized patients with schizophrenia refractory to treatment with first-generation antipsychotics: a 4-week, flexible-dose, single-blind, exploratory, pilot trial.
    Sacchetti E, Panariello A, Regini C, Valsecchi P.
    Schizophr Res; 2004 Aug 01; 69(2-3):325-31. PubMed ID: 15469204
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study.
    Mullen J, Jibson MD, Sweitzer D.
    Clin Ther; 2001 Nov 01; 23(11):1839-54. PubMed ID: 11768836
    [Abstract] [Full Text] [Related]

  • 40. Multiple dose pharmacokinetics of quetiapine and some of its metabolites in Chinese suffering from schizophrenia.
    Li KY, Li X, Cheng ZN, Peng WX, Zhang BK, Li HD.
    Acta Pharmacol Sin; 2004 Mar 01; 25(3):390-4. PubMed ID: 15000896
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.